Cocrystal Pharma, INC. (COCP) — 10-Q Filings

All 10-Q filings from Cocrystal Pharma, INC.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (4)

Cocrystal Pharma Narrows Q3 Loss Amid R&D Cuts, Liquidity Concerns Persist — Nov 14, 2025 Risk: high
Cocrystal Pharma, Inc. reported a net loss of $2.049 million for the three months ended September 30, 2025, a significant improvement from the $4.939 million ne
Cocrystal Pharma Files Q1 2025 10-Q — May 15, 2025 Risk: medium
Cocrystal Pharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company, previously known as BIOZONE PHARMACEUTICALS, INC., is based
Cocrystal Pharma Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
Cocrystal Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business opera
Cocrystal Pharma, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
Cocrystal Pharma, Inc. (COCP) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Cocrystal Pharma, Inc. filed a 10-Q report for the period ending Mar

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX